Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
Date: October 19, 2020
Issue #:
1609Summary:
The antisense oligonucleotide viltolarsen (Viltepso–
NS Pharma) has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in patients who have mutations of the
dystrophin gene that are amenable to exon 53 skipping
(DMD-53). It is the second drug to be approved for this
indication; the antisense oligonucleoti de golodirsen(Vyondys 53) was approved in 2019. (Source: The Medical Letter)
Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
Date: October 19, 2020
Issue #:
1609Summary:
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi– Sunovion) for acute, intermittent treatment
of " off " episodes in patients with Parkinson ' s disease
(PD). A subcutaneous formulation of apomorphine(Apokyn) has been available for years for the same
indication in patients with advanced PD. (Source: The Medical Letter)
Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Antiviral Drugs for Influenza for 2020-2021
Date: November 2, 2020
Issue #:
1610Summary:
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory failure,
and death can occur, especially in patients at increased
risk for influenza complications (see Table 1).
Antiviral drugs recommended for treatment and
chemoprophylaxis of influenza this season are listed
in Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC atwww.cdc.gov/flu. (Source: The Medical Letter)
Source: The Medical Letter - September 29, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Caplacizumab (Cablivi) for iTTP
Date: October 19, 2020
Issue #:
1609Summary:
Caplacizumab-yhdp (Cablivi– Sanofi /Genzyme), a
von Willebrand factor-directed antibody fragment, has
been approved by the FDA for use in combination with
plasma exchange and immunosuppressive therapy
for treatment of immune-mediated thrombotic
thrombocytopenic purpura (iTTP; formerly called
acquired thrombotic thrombocyto penic purpura
[aTTP]) in adults. It is the first drug to be approved in
the US for this indication. (Source: The Medical Letter)
Source: The Medical Letter - September 29, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Timing of Remdesivir for COVID-19
Date: October 19, 2020
Issue #:
1609Summary:
Remdesivir (Veklury– Gilead), an investigational
antiviral drug administered by IV infusion, is now
available through an FDA Emergency Use Authorization
(EUA) for treatment of COVID-19 in all hospitalized
patients. An earlier EUA limited use of the drug to
patients hospitalized with severe disease. (Source: The Medical Letter)
Source: The Medical Letter - September 28, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Lyumjev - A New Insulin Lispro for Diabetes
Date: October 19, 2020
Issue #:
1609Summary:
The FDA has approved insulin lispro-aabc (Lyumjev–
Lilly), a faster-acting formulation of insulin lispro(Humalog), for treatment of type 1 and type 2 diabetes
in adults.Fiasp, a faster-acting formulation of insulin
aspart(Novolog), was approved in 2017. (Source: The Medical Letter)
Source: The Medical Letter - September 14, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)
Date: September 21, 2020
Issue #:
1607Summary:
View the Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein tables (Source: The Medical Letter)
Source: The Medical Letter - September 11, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
In Brief: Canagliflozin and Lower Limb Amputations
Date: September 21, 2020
Issue #:
1607Summary:
The FDA has removed a boxed warning from the labeling
of products containing the sodium-glucose co-transporter
2 (SGLT2) inhibitor canagliflozin (Invokana,Invokamet,Invokamet XR) that described an increased risk of lower
limb amputation associated with use of the drug. Package
inserts for canagliflozin products still contain a standard
warning about a risk of lower limb amputation. (Source: The Medical Letter)
Source: The Medical Letter - September 11, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Table: Correct Use of Inhalers for COPD (online only)
Date: September 7, 2020
Issue #:
1606Summary:
View the Table: Correct Use of Inhalers for COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Advair Aerospan AirDuo Albuterol Alvesco Anoro Ellipta ArmonAir Arnuity Ellipta Asmanex Asthma Atrovent Beclomethasone Bevespi Aerosphere Breo Ellipta Breztri Aerosphere Budesonide ciclesonide Combivent COP Source Type: research
Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)
Date: September 7, 2020
Issue #:
1606Summary:
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Advair Aermony Respiclick Alvesco ArmonAir Arnuity Ellipta Asmanex Beclomethasone dipropionate Breo Ellipta Breztri Aerosphere Budesonide Budesonide/formoterol ciclesonide COPD Flovent fluticasone furoate Fluticasone propiona Source Type: research
Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)
Date: September 7, 2020
Issue #:
1606Summary:
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Advair AirDuo Anoro Ellipta arformoterol Bevespi Aerosphere Breo Ellipta brovana Budesonide/formoterol COPD Duaklir Genuair Duaklir Pressair fluticasone furoate Fluticasone propionate fluticasone/vilanterol Glycopy Source Type: research
Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)
Date: September 7, 2020
Issue #:
1606Summary:
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Albuterol Atrovent Combivent COPD Ipratropium Levalbuterol ProAir ProAir RespiClick Proventil Salbutamol Xopenex Source Type: research
A New Indication for Esketamine Nasal Spray (Spravato)
Date: September 21, 2020
Issue #:
1607Summary:
Esketamine (Spravato– Janssen), an intranasal
N-methyl-D-aspartate (NMDA) receptor antagonist
that was previously approved by the FDA for treatmentresistant
depression,1 has now been approved for
treatment of depressive symptoms in adults with
major depressive disorder (MDD) and acute suicidal
ideation or behavior. E sketamine is the S-enantiomer
of the anesthetic ketamine (Ketalar, and generics).
It is the first drug to be approved for this indication.
Most clinical trials of antidepressants have excluded
patients with acute suici...
Source: The Medical Letter - August 18, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Drugs for Migraine
Date: October 5, 2020
Issue #:
1608Summary:
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine headache pain in most patients without
vascular disease. Early treatment of pain when it is
still mild to moderate in intensity improves headache
response and reduces the risk of recurrence. (Source: The Medical Letter)
Source: The Medical Letter - August 18, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Acetaminophen acupuncture Aimovig Ajovy Almotriptan Amerge Amitriptyline Antidepressants Antiepileptics Aspirin Atenolol Aventyl Beta blockers Bisoprolol Botox Botulinum toxin Butalbital Cafergot Caffeine Cambia Can Source Type: research
Influenza Vaccine for 2020-2021
Date: September 21, 2020
Issue #:
1607Summary:
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness and symptoms
that might be confused with those of COVID-19.
Available vaccines and recommendations for specific
patient populations for the 2020-2021 season are listed
in Ta bles 2 and 3. Lower rates of influenza illness have
been observed this season in the Southern Hemisphere,
probably because of masking, social distancing, sch...
Source: The Medical Letter - August 18, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
